title: Clinical use of proteasome inhibitors in the treatment of multiple myeloma.
abstract: Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
authors.affiliation: Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA. noah.merin@med.usc.edu.
authors.forename: Noah M
authors.initials: NM
authors.lastname: Merin
authors.affiliation: Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA. kevin.kelly@med.usc.edu.
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Kelly